GLOW is a vendor-branded multi-peptide blend that appears on every major
research vendor catalogue VialTalk tracks, and is one of the most-asked-about
"named" stacks in community discussions of cosmetic and tissue-repair research.
This monograph lays out what is actually in a GLOW vial, what each component
contributes mechanistically, what the literature does and does not show for the
combination, and what to demand of a vendor before evaluating any product.
Composition.
GLOW is a fixed 70 mg blend of three peptides combined into a single lyophilized vial. The canonical recipe, confirmed from Voltera Sciences' product page, is BPC-157 10 mg + GHK-Cu 50 mg + TB-500 10 mg. The same 70 mg configuration is sold by Glacier Aminos, Ion Peptide, Ramp Peptides, TriVial BioWorks, and American Aminos & Peptides; ratios across vendors appear to be identical, though buyers should always verify the per-component breakdown on the vendor product page and the batch COA.
What each component contributes.
The blend is built around three peptides whose mechanisms are complementary
rather than overlapping. BPC-157 ("Body Protection Compound-157") is a
15-amino-acid synthetic fragment derived from a sequence found in human gastric
juice; preclinical literature describes effects on angiogenesis (VEGFR2 pathway),
nitric-oxide modulation, and tendon-fibroblast growth-hormone-receptor
interactions. TB-500 is a synthetic peptide corresponding to the 17-21 actin-
binding region of thymosin beta-4; rodent studies report effects on cell
migration, wound contraction, and vascular remodelling. GHK-Cu is a naturally
occurring copper-binding tripeptide (Gly-His-Lys-Cu²⁺) with an unusually well-
characterized literature in dermal biology — it is the only one of the three
with substantial human clinical data, drawn from the cosmetic and wound-care
fields. The naming choice ("GLOW") reflects the blend's positioning toward
skin, hair, and superficial tissue research rather than musculoskeletal work.
Research applications.
GLOW exists because researchers wanted a single vial that combined a "tissue-
repair backbone" (BPC-157 + TB-500, the same pairing that underlies the
Wolverine stack) with a "dermal-active" overlay (GHK-Cu). Reported research
applications in community and preclinical settings include skin and dermal
regeneration models, hair-follicle and scalp research, scar-remodelling and
fibrosis studies, and post-procedure tissue-recovery work. The literature
supporting these applications is overwhelmingly preclinical for BPC-157 and
TB-500 and a mix of cell-culture and small human studies for GHK-Cu; no
combined GLOW formulation has been studied in a published clinical trial. The
blend is a vendor product, not a research molecule.
Administration.
No human clinical trial has established administration parameters for GLOW; VialTalk does not provide community-sourced dosing.
Storage and handling.
Lyophilized GLOW should be kept refrigerated (2–8 °C) and protected from light.
Avoid repeated freeze-thaw cycles.
Quality and COA considerations.
A meaningful COA for a GLOW vial should report identity confirmation (mass spectrometry showing peaks for each of the three peptides at their expected molecular weights), purity by HPLC for each component (≥98% is the practical benchmark), and a verification of the fill weight breakdown that matches the labelled 10/50/10 mg ratio. Underdosing and inconsistent ratios are a known problem in this market; a vial with only a single-line "Peptide Blend ≥98%" purity statement and no per-component breakdown is effectively unverified. Sterility and endotoxin testing should also be reported if the vial is being used in any model that touches injection or tissue contact.
*Research-use note: This monograph is an educational summary of the published
research literature for the GLOW blend. The
combined formulation has not been evaluated in human clinical trials, and none
of the three component peptides is approved for human use in any jurisdiction
known to VialTalk. Nothing here is medical advice or a usage recommendation.*
